Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.7%

22 terminated/withdrawn out of 284 trials

Success Rate

91.6%

+5.1% vs industry average

Late-Stage Pipeline

33%

93 trials in Phase 3/4

Results Transparency

41%

99 of 241 completed trials have results

Key Signals

13 recruiting99 with results19 terminated

Enrollment Performance

Analytics

Phase 1

82(33.2%)

Phase 2

61(24.7%)

Phase 3

56(22.7%)

Phase 4

37(15.0%)

N/A

9(3.6%)

Early Phase 1

2(0.8%)

247Total

Phase 1(82)

Phase 2(61)

Phase 3(56)

Phase 4(37)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (284)

Showing 20 of 284 trials

NCT07335588Phase 3Recruiting

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

Role: lead

NCT05958407Phase 3Completed

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

Role: lead

NCT06013969Phase 4Active Not Recruiting

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Role: lead

NCT06624670Phase 3Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Role: lead

NCT03886246Phase 2Active Not Recruiting

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

Role: lead

NCT07013201Phase 2Recruiting

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

Role: lead

NCT07487948Phase 2Recruiting

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Role: collaborator

NCT06311682Phase 3Recruiting

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Role: lead

NCT06773455Phase 4Terminated

Tralokinumab for Dupilumab Failures

Role: collaborator

NCT05295732Phase 3Completed

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

Role: lead

NCT07603193Enrolling By Invitation

Real-World Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment With Delgocitinib Cream

Role: lead

NCT04154293Phase 2Completed

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

Role: lead

NCT05388760Phase 2Completed

Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)

Role: lead

NCT06444867Phase 1Completed

A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968

Role: lead

NCT05355818Phase 3Completed

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema

Role: lead

NCT03995550Phase 1Withdrawn

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese

Role: lead

NCT05682976Completed

Ophthalmological Adverse Events of Tralokinumab in AD

Role: collaborator

NCT02664805Phase 2Completed

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

Role: lead

NCT05050279Early Phase 1Completed

A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People

Role: lead

NCT04883333Phase 1Completed

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults

Role: lead